A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT ID: NCT05995353
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
118 participants
INTERVENTIONAL
2023-12-11
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1(including Sub-cohort 1A) will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 118 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102
An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
NCT05841537
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03105128
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PK Cohort 1: SS1
Cohort 1 (including Sub-cohort 1A) will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.
Risankizumab
Intravenous (IV) Infusion
PK Cohort 1: SS2 Dose A
Cohort 1 (including Sub-cohort 1A) will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 1: SS2 Dose B
Cohort 1 (including Sub-cohort 1A) will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 1: SS3 Dose A
Cohort 1 (including Sub-cohort 1A) will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 1: SS3 Dose B
Cohort 1 (including Sub-cohort 1A) will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
Risankizumab
Intravenous (IV) Infusion
PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Risankizumab
Subcutaneous (SC) Injection
PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Risankizumab
Subcutaneous (SC) Injection
Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
Risankizumab
Intravenous (IV) Infusion
Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Risankizumab
Subcutaneous (SC) Injection
Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Risankizumab
Subcutaneous (SC) Injection
Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Risankizumab
Subcutaneous (SC) Injection
Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Risankizumab
Subcutaneous (SC) Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risankizumab
Intravenous (IV) Infusion
Risankizumab
Subcutaneous (SC) Injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have moderately to severely active CD, as defined by the PCDAI score \> 30 assessed at Baseline
* Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
* Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Exclusion Criteria
* Any of the following medical disorders:
1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.
2. A diagnosis of CD prior to 2 years of age.
3. A diagnosis or suspected diagnosis of a primary immunodeficiency.
4. Currently known complications of CD such as:
* Active abscess (abdominal or perianal);
* Symptomatic bowel strictures;
* \> 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
* Fulminant colitis;
* Toxic megacolon;
* Or any other manifestation that might require surgery while enrolled in the study.
5. Ostomy or ileoanal pouch.
6. Diagnosis of short gut or short bowel syndrome.
7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of \>3 bowel resections.
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Children's Hospital /ID# 255766
Phoenix, Arizona, United States
Arkansas Children's Hospital /ID# 255762
Little Rock, Arkansas, United States
UCSF Benioff Children's Hospital - Oakland /ID# 258327
Oakland, California, United States
Childrens Hospital Colorado - Aurora /ID# 255764
Aurora, Colorado, United States
Arnold Palmer Hospital for Children Center Digestive Health & Nutrition - Orland /ID# 255437
Orlando, Florida, United States
Indiana University Health Riley Hospital for Children /ID# 256454
Indianapolis, Indiana, United States
Massachusetts General Hospital /ID# 255767
Boston, Massachusetts, United States
MNGI Digestive Health, P. A. /ID# 255366
Minneapolis, Minnesota, United States
Goryeb Childrens Hospital /ID# 256452
Morristown, New Jersey, United States
Icahn School of Medicine at Mount Sinai /ID# 254880
New York, New York, United States
Cleveland Clinic - Cleveland /ID# 256453
Cleveland, Ohio, United States
Uza /Id# 255114
Edegem, Antwerpen, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 255108
Brussels, Brussels Capital, Belgium
Universitair Ziekenhuis Brussel /ID# 255109
Jette, Brussels Capital, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 255620
Liège, Liege, Belgium
Universitair Ziekenhuis Leuven /ID# 255098
Leuven, Vlaams-Brabant, Belgium
Hospital Universite Enfants Reine Fabiola /ID# 255112
Brussels, , Belgium
UMHAT Sveti Georgi /ID# 255386
Plovdiv, , Bulgaria
Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
Sofia, , Bulgaria
UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
Varna, , Bulgaria
Alberta Children's Hospital /ID# 255357
Calgary, Alberta, Canada
Edmonton Clinic Health Academy /ID# 255361
Edmonton, Alberta, Canada
BC Children's Hospital /ID# 255359
Vancouver, British Columbia, Canada
London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
London, Ontario, Canada
Beijing Children's Hospital /ID# 256081
Beijing, Beijing Municipality, China
Peking University Third Hospital /ID# 255876
Beijing, Beijing Municipality, China
Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
Guangzhou, Guangdong, China
Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
Zhengzhou, Henan, China
Hunan Children's Hospital /ID# 255610
Changsha, Hunan, China
Jiangxi Provincial Children's Hospital /ID# 255564
Nanchang, Jiangxi, China
Shengjing Hospital of China Medical University /ID# 255563
Shenyang, Liaoning, China
Children's Hospital of Shanghai /ID# 255531
Shanghai, Shanghai Municipality, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
Shanghai, Shanghai Municipality, China
Všeobecná Fakultní Nemocnice v Praze /ID# 256096
Prague, Praha 17, Czechia
Fakultní nemocnice v Motole /ID# 256547
Prague, Praha 5, Czechia
CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
Tours, Centre-Val de Loire, France
CHU Bordeaux - Hopital Pellegrin /ID# 257060
Bordeaux, Nouvelle-Aquitaine, France
Hospices Civils de Lyon - Hôpital Femme Mère Enfant /ID# 255443
Bron, Rhone, France
AP-HP - Hopital Necker /ID# 255608
Paris, , France
CHU Toulouse - Hopital Paule de Viguier /ID# 255609
Toulouse, , France
Dr. von Haunerschen Kinderspital /ID# 255577
Munich, Bavaria, Germany
Universitaetsklinikum Muenster /ID# 256762
Münster, North Rhine-Westphalia, Germany
Schneider Children's Medical Center /ID# 254950
Petah Tikva, Central District, Israel
Shaare Zedek Medical Center /ID# 254951
Jerusalem, Jerusalem, Israel
IRCCS Istituto Giannina Gaslini /ID# 255262
Genoa, Genova, Italy
Azienda Ospedaliera Universitaria Federico II /ID# 255045
Naples, Napoli, Italy
Ospedale Pediatrico Bambino Gesù /ID# 255043
Rome, Roma, Italy
Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
Messina, , Italy
Aichi Children'S Health And Medical Center /ID# 272085
Ōbu, Aichi-ken, Japan
Tsujinaka Hospital - Kashiwanoha /ID# 268409
Kashiwa-shi, Chiba, Japan
Kurume University Hospital /ID# 268418
Kurume-shi, Fukuoka, Japan
Gunma University Hospital /ID# 270560
Maebashi, Gunma, Japan
Japanese Red Cross Kumamoto Hospital /ID# 268586
Kumamoto, Kumamoto, Japan
Osaka Women's and Children's Hospital /ID# 268419
Izumi-Shi, Osaka, Japan
Saitama Children's Medical Center /ID# 268410
Saitama-shi, Saitama, Japan
Institute of Science Tokyo Hospital /ID# 269175
Bunkyo-ku, Tokyo, Japan
Tokyo Metropolitan Children's Medical Center /ID# 268415
Fuchu-shi, Tokyo, Japan
National Center For Child Health And Development /ID# 268420
Setagaya City, Tokyo, Japan
Amsterdam UMC, locatie AMC /ID# 254827
Amsterdam, North Holland, Netherlands
Gastromed Sp. z o.o /ID# 255939
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
Warsaw, Masovian Voivodeship, Poland
Puerto Rico Health Institute /ID# 255071
Dorado, , Puerto Rico
Clinical Research Puerto Rico /ID# 266479
San Juan, , Puerto Rico
Seoul National University Hospital /ID# 255318
Seoul, Seoul Teugbyeolsi, South Korea
Yonsei University Health System Severance Hospital /ID# 256976
Seoul, Seoul Teugbyeolsi, South Korea
Samsung Medical Center /ID# 255284
Seoul, Seoul Teugbyeolsi, South Korea
Kyungpook National University Chilgok Hospital /ID# 255817
Daegu, , South Korea
Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
Ferrol, A Coruna, Spain
Hospital Infantil Universitario Nino Jesus /ID# 255012
Madrid, , Spain
Hospital Regional Universitario de Malaga /ID# 257553
Málaga, , Spain
Karolinska University Hospital Solna /ID# 255240
Solna, Stockholm County, Sweden
Sodersjukhuset /ID# 255239
Stockholm, Stockholm County, Sweden
Sahlgrenska Universitetssjukhuset /ID# 255236
Gothenburg, Västra Götaland County, Sweden
Kinderspital Zurich - Eleonorenstiftung /ID# 255337
Zurich, Canton of Zurich, Switzerland
Inselspital, Universitaetsspital Bern /ID# 255321
Bern, , Switzerland
National Taiwan University Hospital /ID# 255679
Taipei City, Taipei, Taiwan
Changhua Christian Hospital /ID# 256082
Changhua City, Changhua County, , Taiwan
Gazi University Medical Faculty /ID# 255086
Ankara, , Turkey (Türkiye)
Sariyer Hamidiye Etfal Eğitim Ve Araştirma Hastanesi /ID# 257143
Istanbul, , Turkey (Türkiye)
Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
Istanbul, , Turkey (Türkiye)
Kocaeli University Med Faculty /ID# 256922
Kocaeli, , Turkey (Türkiye)
Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
Sheffield, England, United Kingdom
Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
London, Greater London, United Kingdom
Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Site Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502050-14-00
Identifier Type: OTHER
Identifier Source: secondary_id
M16-194
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.